On October 19, 2021 Race Oncology ("Race") reported that it has been issued a new patent (US patent no. 11,147,800) on its cancer drug, Zantrene (bisantrene dihydrochloride), by the United States Patent and Trademarks Office (USPTO) (Press release, Race Oncology, OCT 19, 2021, View Source [SID1234591504]). This patent expires on 25 July 2034.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This is Race’s sixth granted patent on Zantrene in the United States.

"The new US patent provides Race with further protection around uses of Zantrene (and related chemical structures) that improve the efficacy of Zantrene treatments"

Race’s CEO Phillip Lynch
This new patent further expands the therapeutic utility of Zantrene (and related chemical structures), in particular – methods that improve the therapeutic efficacy of Zantrene and reduce side effects.

The new patent builds on Race’s existing Zantrene patents granted in the USA in 2018 (US 9,993,460 and US 9,974,774), 2019 (US 10,500,192), 2020 (US 10,548,876) and in 2021 (US 11,135,201), further strengthening Race’s growing IP position for Zantrene.